Compare · GLP-1 agonist
CagriSema vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| CagriSema | VK2735 | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
CagriSema
CagriSema is one of the most heavily studied combination products in the obesity-drug pipeline, and also a useful case study in why "strong trial data" and "proven, approved, and better than the alternatives" are not the same thing. It is a once-weekly injectable that fixes two peptides into a…
VK2735
VK2735 is an investigational obesity drug from Viking Therapeutics. It belongs to the incretin class — the same broad family as semaglutide and tirzepatide — and has generated a lot of attention because its early human data look strong and because Viking is developing both an injectable and an oral…